Loading...
Market
What will be the valuation of GRO Biosciences by end of 2024?
3
GRO Biosciences•Atlas Venture•Access Biotechnology•Leaps by Bayer•Redmile Group•Digitalis Ventures•iEndeavors•Pillar•Dan
Resolution / Starting Odds
Less than $200M • 25%
$200M - $400M • 25%
$400M - $600M • 25%
More than $600M • 25%
Financial news outlets, company announcements
Story
GRO Biosciences Secures $60.3M Series B Financing Co-Led by Atlas Venture and Access Biotechnology
Jul 19, 2024, 12:05 PM
GRO Biosciences has successfully closed a $60.3 million Series B financing round, co-led by Atlas Venture and Access Biotechnology. The funds will be used to advance its pipeline, which focuses on incorporating non-standard amino acid (NSAA) chemistries into therapies. This round also saw participation from previous investors, including Leaps by Bayer, Redmile Group, Digitalis Ventures, and iEndeavors. The financing marks a significant milestone for the company, which has been backed by Pillar since its pre-seed stage. Dan and his team have been pivotal in developing the GRO platform and product pipeline.
View original story
Similar markets
Below $3 billion • 25%
$3 billion to $4 billion • 25%
$4 billion to $5 billion • 25%
Above $5 billion • 25%
Less than $100B • 25%
$100B to $150B • 25%
$150B to $200B • 25%
More than $200B • 25%
Less than $250M • 33%
$250M to $500M • 33%
More than $500M • 34%
Under $500M • 25%
$500M - $1B • 25%
$1B - $1.5B • 25%
Over $1.5B • 25%
Less than $50M • 25%
$50M to $100M • 25%
$100M to $150M • 25%
More than $150M • 25%
Above $25 • 25%
Between $20 and $25 • 25%
Between $15 and $20 • 25%
Below $15 • 25%
Less than $5 billion • 25%
$5 billion to $6 billion • 25%
$6 billion to $7 billion • 25%
More than $7 billion • 25%
Less than $1.5 billion • 25%
$1.5 billion to $2 billion • 25%
$2 billion to $2.5 billion • 25%
More than $2.5 billion • 25%
Below $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
Above $3 billion • 25%
